Animal Blood Plasma and Derivatives Market Size, Share, Growth, and Industry Analysis, By Type (Immunoglobulin, Fibrinogen, Serum albumin, Fetal bovine serum, Thrombin, New born calf serum), Regional Insights and Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

ANIMAL BLOOD PLASMA AND DERIVATIVES MARKET OVERVIEW

The global animal blood plasma and derivatives market size stood at USD 1.21 billion in 2024 and is projected to reach USD 1.28 billion in 2025, growing further to USD 1.99 billion by 2033 at an estimated CAGR of 5.71% from 2025 to 2033 during the forecast year.

The animal blood plasma and derivatives market is a crucial sector within the global biopharmaceutical industry. It encompasses the collection, processing, and distribution of blood plasma and its derived products from various animal sources, including bovine and porcine. These products play a vital role in pharmaceuticals, veterinary medicine, and research applications.

The market has witnessed steady growth due to increasing demand for plasma-derived therapies, rising prevalence of chronic diseases, and advancements in bioprocessing techniques. Additionally, the growing awareness about the therapeutic benefits of animal-derived plasma products has further propelled market expansion.

ANIMAL BLOOD PLASMA AND DERIVATIVES MARKET KEY FINDINGS

• Market Size and Growth: Global animal blood plasma and derivatives market size was projected at USD 1.21 billion in 2024 and is expected to hit USD 1.99 billion by 2033 with a CAGR of 5.71% during the forecast period.

• Key Market Driver: The increasing demand for high-quality animal-derived proteins in various industries, including pharmaceuticals and food, is a significant driver. For instance, the global pet industry reached USD 261 billion in 2022, reflecting a year-on-year increase of 11.3%, indicating a growing market for pet-related products.

• Major Market Restraint: Stringent regulations regarding animal-derived products and ethical concerns related to animal welfare pose challenges to market growth. Additionally, nearly 40% of consumers express interest in reducing their meat consumption, highlighting a shift towards alternative proteins and potentially impacting the demand for animal-derived products.

• Emerging Trends: Innovations in plasma fractionation techniques, such as advanced filtration and purification processes, are leading to the production of higher quality plasma-derived products. Moreover, there's a growing focus on utilizing animal blood plasma derivatives in niche therapeutic areas, including regenerative medicine and personalized medicine.

• Regional Leadership: North America leads the market, with a valuation of USD 2.45 billion in 2023, expected to grow to USD 4.0 billion by 2032, driven by advanced healthcare infrastructure and high demand for blood plasma products.

• Competitive Landscape: The market is moderately concentrated, with key players focusing on product innovation and strategic partnerships to enhance their market presence. For example, Grifols, S.A., a leading producer of plasma-derived medicines, reported revenues of €7.2 billion in 2024 and operates 15 industrial facilities in seven countries.

• Market Segmentation: The market is segmented by application into food industry, pharmaceuticals, animal feed, and others. The food industry is a major application area, leveraging animal blood plasma and derivatives to enhance the nutritional value and functional properties of various food products.

• Recent Development: CSL has invested USD 900 million in a plasma fractionation plant in Melbourne, aiming to expand its albumin production capabilities and meet growing global demand.

COVID-19 IMPACT

Market Growth Restrained by Pandemic due to Supply Chain Disruptions

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic has had a notable impact on the animal blood plasma and derivatives market. On one hand, the increased focus on healthcare and bio therapeutics during the pandemic has led to a surge in demand for blood plasma and its derivatives for various medical applications, including the development of therapies and vaccines. On the other hand, disruptions in the supply chain and logistical challenges have presented hurdles for the collection and processing of animal blood products. Additionally, the economic impact of the pandemic may have influenced the purchasing behavior of consumers and healthcare providers, potentially affecting market dynamics. Overall, while there has been an increased demand for certain blood plasma products, the market has also faced challenges related to production and distribution during the pandemic.

LATEST TRENDS

Emerging Therapeutic Applications and Technological Advancements Leads Growth In The Market

One of the latest trends in the animal blood plasma and derivatives market is the emergence of novel therapeutic applications and technological advancements. Innovations in plasma fractionation techniques, such as the development of advanced filtration and purification processes, are leading to the production of higher quality and more specific plasma-derived products. Moreover, there is a growing focus on utilizing animal blood plasma derivatives in niche therapeutic areas, including regenerative medicine, immunotherapy, and personalized medicine. These trends are reshaping the market landscape, offering new opportunities for market players to meet evolving healthcare needs and improve patient outcomes. Additionally, ongoing research in areas like nanotechnology and bioprocessing is expected to further enhance the efficacy and safety of plasma-derived products, driving continued growth and innovation in this dynamic market.

• Expansion of Plasma Collection Centers: The global blood plasma derivatives market reached a value of nearly $48.3 billion in 2023, having grown at a compound annual growth rate (CAGR) of 8.8% since 2018.

• Growth in Immunoglobulin Segment: The immunoglobulin market was the largest segment of the blood plasma derivatives market segmented by type, accounting for 46.2% or $22.3 billion of the total in 2023. 

Request a Free sample to learn more about this report

ANIMAL BLOOD  PLASMA AND DERIVATIVES MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Immunoglobulin, Fibrinogen, Serum albumin, Fetal bovine serum, Thrombin, New born calf serum.

• Immunoglobulins derived from animal blood plasma play a crucial role in the pharmaceutical industry.

• Animal blood plasma-derived fibrinogen is a vital component in haemostatic therapies, aiding in blood clotting. Market demand is driven by surgical and trauma care applications.

• Animal blood plasma-derived serum albumin is a vital protein used in pharmaceuticals, diagnostics, and research, driving growth in the market.

• Fetal bovine serum, a rich source of nutrients for cell culture, is a critical component in biopharmaceutical and research applications, driving market demand.

• Animal blood plasma-derived thrombin, a crucial clotting enzyme, finds applications in surgery and wound care, bolstering the market's growth.

• Newborn calf serum, sourced from bovine calves, is a valuable component in cell culture media, supporting growth in the biotechnology sector.

By Application

Based on application, the market can be divide into Food and Beverages, Pharmaceuticals, Cosmetics, Feed and Others. 

DRIVING FACTORS

Biotechnology Advancements to Propel the Market Growth

Advancements in biotechnology have significantly propelled and expanded the animal blood plasma and derivatives market share. Cutting-edge techniques in cell culture and bioprocessing have increased the demand for serum albumin, immunoglobulins, and other derivatives sourced from animal blood plasma. These components are crucial in cell culture media, vaccines, and therapeutic products. Furthermore, improvements in purification and processing technologies have enhanced the quality and yield of these products, driving their adoption across various industries.

Rising Demand in Healthcare to Drive the Market Growth

The healthcare sector has been a major driver of the animal blood plasma and derivatives market. Immunoglobulins, derived from animal blood plasma, are essential in treating a range of immune-related disorders, including primary immunodeficiency diseases. The COVID-19 pandemic has further underscored the importance of these products in developing vaccines and therapies. Additionally, serum albumin, with its critical role in maintaining colloidal osmotic pressure in the blood, finds extensive application in critical care settings. As the global population continues to age and face various health challenges, the demand for these essential blood plasma products is anticipated to remain robust.

• Rising Pet Industry Expenditure: The global pet industry reached $261 billion in 2022, a year-on-year increase of 11.3%, indicating a growing market for pet-related products, including those derived from animal blood plasma.

• High Pet Ownership in the U.S.: According to the American Pet Products Association (APPA), 66% of American households keep pets, and the total industry sales were about $136.8 billion, an increase of 10.8% over 2021.

RESTRAINING FACTOR

Regulatory Challenges to Poses a Significant Restrain on the Market Growth

Navigating complex regulatory frameworks poses a significant restraining factor for the animal blood plasma and derivatives market. Strict guidelines govern the collection, processing, and distribution of these products to ensure safety and quality. Adhering to these standards demands substantial investments in compliance measures, which can be a barrier for smaller players. Additionally, variations in regulatory requirements across different regions and countries can lead to logistical complexities, hindering market access and growth.

• Regulatory Challenges: The industry faces challenges such as regulatory constraints and ethical considerations regarding animal welfare practices, which can hinder market growth.

• Consumer Shift Towards Plant-Based Alternatives: Nearly 40% of consumers express interest in reducing their meat consumption, highlighting a shift towards alternative proteins and potentially impacting the demand for animal-derived products.

• Request a Free sample to learn more about this report

•  

ANIMAL BLOOD  PLASMA AND DERIVATIVES MARKET REGIONAL INSIGHTS

North America to Dominate the Market owing to Advanced Research Infrastructure

North America is poised to dominate the animal blood plasma and derivatives market growth. With a well-established biopharmaceutical sector, advanced research infrastructure, and stringent regulatory standards, the region is at the forefront of innovation and production in this field. Additionally, a high prevalence of chronic diseases and a strong focus on healthcare advancements contribute to the robust demand for products derived from animal blood plasma. The presence of key market players and extensive R&D activities further solidify North America's position as the leading market for animal blood plasma and derivatives.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market through Innovation and Market Expansion

Several key industry players are driving innovation and market expansion in the animal blood plasma and derivatives sector. Companies like Grifols, CSL Limited, Takeda Pharmaceuticals, and Kedrion Biopharma are at the forefront of research and development, continuously introducing novel products and technologies. They invest heavily in advanced processing techniques, ensuring high-quality derivatives. Additionally, strategic collaborations, mergers, and acquisitions enable these companies to expand their market reach and offer a comprehensive portfolio of products to meet diverse industry needs.

• Lake Immunogenics, Inc. (U.S.): Lake Immunogenics has produced over 35,000 liters of plasma as raw material for antibody production under cGMP-compliant projects.

List of Top Animal Blood Plasma And Derivatives Companies

• ANZCO Foods Ltd. (New Zealand)
• Lake Immunogenics, Inc. (U.S.)
• Kraeber and Co GmbH (Germany)
• Auckland BioSciences Ltd. (New Zealand)
• Bovogen Biologicals Pty Ltd. (Australia)
• Rocky Mountain Biologicals Inc. (U.S.)
• Proliant Inc. (U.S.)
• Merck KGaA (Germany)
• LAMPIRE Biological Laboratories, Inc. (U.S.)
• Thermo Fisher Scientific, Inc. (U.S.)

INDUSTRIAL DEVELOPMENT

2022: The industrial development of the animal blood plasma and derivatives market has seen significant progress in recent years. Advances in bioprocessing technologies and purification methods have improved the efficiency and quality of production. This has led to increased yields of high-quality products, meeting the growing demand in various industries. Moreover, the market has witnessed a surge in research and development activities, leading to the introduction of innovative products and applications. These include specialized cell culture media, advanced vaccines, and cutting-edge therapies, further expanding the market's scope.

REPORT COVERAGE

The animal blood plasma and derivatives market is a dynamic and essential sector within the biopharmaceutical industry. It encompasses the collection, processing, and distribution of vital plasma-derived products for a range of therapeutic and research applications. The market has seen steady growth, driven by increasing demand for plasma-derived therapies and advancements in bioprocessing techniques. Key regions like North America and Europe have traditionally dominated, but emerging economies in Asia-Pacific are showing substantial growth potential. Additionally, the industry has demonstrated resilience in the face of challenges, such as the COVID-19 pandemic, highlighting its critical role in global healthcare.